Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
MYOS's Cash to Debt is ranked higher than
94% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. MYOS: No Debt )
MYOS' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

Equity to Asset 0.88
MYOS's Equity to Asset is ranked higher than
93% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. MYOS: 0.88 )
MYOS' s 10-Year Equity to Asset Range
Min: 0.17   Max: 0.96
Current: 0.88

0.17
0.96
Interest Coverage No Debt
MYOS's Interest Coverage is ranked higher than
84% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. MYOS: No Debt )
MYOS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 21.47
M-Score: 0.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -128.60
MYOS's Operating margin (%) is ranked lower than
53% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. MYOS: -128.60 )
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42   Max: -128.6
Current: -128.6

-4642.42
-128.6
Net-margin (%) -128.48
MYOS's Net-margin (%) is ranked lower than
53% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. MYOS: -128.48 )
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54   Max: -128.48
Current: -128.48

-5653.54
-128.48
ROE (%) -127.63
MYOS's ROE (%) is ranked lower than
56% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYOS: -127.63 )
MYOS' s 10-Year ROE (%) Range
Min: -1180.8   Max: -63.15
Current: -127.63

-1180.8
-63.15
ROA (%) -111.13
MYOS's ROA (%) is ranked lower than
57% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. MYOS: -111.13 )
MYOS' s 10-Year ROA (%) Range
Min: -600   Max: -59.95
Current: -111.13

-600
-59.95
ROC (Joel Greenblatt) (%) -501.41
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. MYOS: -501.41 )
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -153200   Max: -501.41
Current: -501.41

-153200
-501.41
EBITDA Growth (%) 1587.20
MYOS's EBITDA Growth (%) is ranked higher than
100% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MYOS: 1587.20 )
MYOS' s 10-Year EBITDA Growth (%) Range
Min: -37   Max: 1587.2
Current: 1587.2

-37
1587.2
EPS Growth (%) 1588.70
MYOS's EPS Growth (%) is ranked higher than
100% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. MYOS: 1588.70 )
MYOS' s 10-Year EPS Growth (%) Range
Min: -37   Max: 1588.7
Current: 1588.7

-37
1588.7
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.90
MYOS's P/B is ranked higher than
57% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYOS: 4.90 )
MYOS' s 10-Year P/B Range
Min: 0.04   Max: 6
Current: 4.9

0.04
6
P/S 0.50
MYOS's P/S is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MYOS: 0.50 )
MYOS' s 10-Year P/S Range
Min: 0.13   Max: 10
Current: 0.5

0.13
10
EV-to-EBIT -10.81
MYOS's EV-to-EBIT is ranked higher than
59% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. MYOS: -10.81 )
MYOS' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 1.7
Current: -10.81

0.1
1.7
Current Ratio 6.10
MYOS's Current Ratio is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. MYOS: 6.10 )
MYOS' s 10-Year Current Ratio Range
Min: 0.03   Max: 27.24
Current: 6.1

0.03
27.24
Quick Ratio 5.30
MYOS's Quick Ratio is ranked higher than
90% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. MYOS: 5.30 )
MYOS' s 10-Year Quick Ratio Range
Min: 0.03   Max: 26.31
Current: 5.3

0.03
26.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.40
MYOS's Price/Net Cash is ranked higher than
89% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYOS: 13.40 )
MYOS' s 10-Year Price/Net Cash Range
Min: 0.12   Max: 14.43
Current: 13.4

0.12
14.43
Price/Net Current Asset Value 8.70
MYOS's Price/Net Current Asset Value is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYOS: 8.70 )
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 0.11   Max: 9.33
Current: 8.7

0.11
9.33
Price/Tangible Book 6.50
MYOS's Price/Tangible Book is ranked higher than
61% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. MYOS: 6.50 )
MYOS' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 7
Current: 6.5

0.1
7
Price/Median PS Value 0.90
MYOS's Price/Median PS Value is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. MYOS: 0.90 )
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 16
Current: 0.9

0.01
16

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 23 2014
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building... Jul 22 2014
MYOS Corp. Tackles Muscles Health Jul 22 2014
8:12 am MYOS reports positive top-line clinical study results of Fortetropin's muscle building... Jul 22 2014
MYOS reports positive top-line clinical study results for Fortetropin Jul 22 2014
MYOS Corporation Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building... Jul 22 2014
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules... Jul 17 2014
MYOS announces agreement with Cloud Pharmaceuticals Jul 17 2014
MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules... Jul 17 2014
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial... Jul 15 2014
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter,... Jul 14 2014
MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur, J. Craig Venter,... Jul 14 2014
MYOS CORP Financials Jul 12 2014
MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market Jul 09 2014
MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market Jul 09 2014
MYOS Corporation Sponsors Sixth Annual Edition of Scientific American Worldview Jun 26 2014
MYOS Corporation Establishes Research Relationship With Rutgers University in Muscle Science Jun 24 2014
MYOS CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 23 2014
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jun 06 2014
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,... May 19 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide